| UNAUDITED COMPARATIVE FINANCIAL INFORMATION |
NOTE 20 – UNAUDITED COMPARATIVE FINANCIAL INFORMATION
The following unaudited financial information for the eight months ended June 30, 2025 is presented for comparative purposes to the eight-month transition period ended June 30, 2026.
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts rounded to the nearest thousand except share amounts)
| Schedule of Unaudited consolidated Statements Of Operation |
|
|
|
|
|
|
|
|
| |
|
8 Months Ended
June 30, |
|
| |
|
2026 |
|
|
2025 |
|
| |
|
|
|
|
(Unaudited) |
|
| Revenues (includes sales to related parties of approximately $70,000 and $52,000, respectively) |
|
$ |
5,868,000 |
|
|
$ |
3,098,000 |
|
| |
|
|
|
|
|
|
|
|
| Cost of revenues |
|
|
1,128,000 |
|
|
|
566,000 |
|
| |
|
|
|
|
|
|
|
|
| Gross profit |
|
|
4,740,000 |
|
|
|
2,532,000 |
|
| |
|
|
|
|
|
|
|
|
| General and administrative expenses |
|
|
10,165,000 |
|
|
|
6,793,000 |
|
| |
|
|
|
|
|
|
|
|
| Loss from operations |
|
|
(5,425,000 |
) |
|
|
(4,261,000 |
) |
| Other income (expense) |
|
|
|
|
|
|
|
|
| Gain on sale of Exotropin interests |
|
|
390,000 |
|
|
|
- |
|
| Interest expense |
|
|
(27,000 |
) |
|
|
(58,000 |
) |
| Change in obligation to repurchase shares |
|
|
(3,000 |
) |
|
|
(5,000 |
) |
| Other income |
|
|
27,000 |
|
|
|
62,000 |
|
| |
|
|
|
|
|
|
|
|
| Net loss |
|
|
(5,038,000 |
) |
|
|
(4,262,000 |
) |
| |
|
|
|
|
|
|
|
|
| Net income attributable to the non-controlling interests |
|
|
36,000 |
|
|
|
- |
|
| |
|
|
|
|
|
|
|
|
| Net loss attributable to Zeo ScientifiX, Inc |
|
$ |
(5,074,000 |
) |
|
$ |
(4,262,000 |
) |
| |
|
|
|
|
|
|
|
|
| Net loss per common share - basic and diluted |
|
$ |
(0.68 |
) |
|
$ |
(0.67 |
) |
| |
|
|
|
|
|
|
|
|
| Weighted average number of common shares outstanding - basic and diluted |
|
|
7,493,536 |
|
|
|
6,356,800 |
|
|